LongeVC Managing Partner Sergey Jakimov Featured in Longevity & Mortality Investor on Investment Strategy
LongeVC managing partner Sergey Jakimov was featured in Longevity & Mortality Investor, discussing the firm's approach to longevity investing and the evolving landscape of the sector.
In conversation with Greg Winterton, Sergey shared LongeVC's standpoint on disease-focused healthspan innovation, the importance of clear clinical endpoints, and how regulatory frameworks shape investment decisions in biotech. He also addressed which areas of longevity science show the most commercial promise and how policy changes, including NIH funding cuts, are reshaping early-stage capital flows.